We present the case of a 13-year-old girl with a huge intracranial mesenchymal chondrosarcoma. She had suffered from severe headache, diplopia, intermittent nausea and vomiting for 1 month. Neurologic examination revealed bilateral blurred optic disc margins and abducens paresis. Magnetic resonance imaging demonstrated a giant, heterogeneous, intensely enhancing mass of 7 × 8 × 6 cm, occupying the bilateral frontal and left high parietal regions and based on the anterior cerebral falx. A presumptive diagnosis of aggressive meningioma was made. The patient underwent bicoronal craniotomy and gross total resection of the tumor. Pathologic examination revealed an extraskeletal mesenchymal chondrosarcoma. She was under regular follow-up and remained free of recurrence after surgery. In addition to the current case, we review previously reported cases of extraskeletal intracranial mesenchymal chondrosarcoma and discuss treatment strategies and outcomes.
Primary sarcomas of the central nervous system are uncommon lesions. Mesenchymal chondrosarcoma represents a very small subset of intracranial sarcomas, which by themselves constitute less than 0.16% of primary intracranial tumors [1, 2] . Mesenchymal chondrosarcoma is a welldefined tumor first described by Lichtenstein and Bernstein in 1959 [3] , and later reported as a primary tumor in extraosseous tissues, including the central nervous system [4] . Intracranial mesenchymal chondrosarcoma is a rare entity. To the best of our knowledge, only 36 cases have been reported in the English literature.
Here, we describe the case of a 13-year-old girl who had headache, diplopia, nausea, and vomiting. Computerized tomography (CT) of the brain revealed an anterior falxbased extraskeletal intracranial mesenchymal chondrosarcoma that was initially thought to be a malignant meningioma. We present CT, magnetic resonance imaging (MRI), and light microscopy results for this aggressive tumor. The treatment strategies are provided after a review of the literature.
CASE PRESENTATION
This 13-year-old girl, a native of Taiwan, was referred to our hospital in December 2000 with a 1-month history of blurred vision, nausea, vomiting, and intermittent headache. These were associated with diplopia and right hemiparesis. Her past medical history was unremarkable. She was initially brought to the ophthalmologic clinic for help, where bilateral optic disc swelling was noted. Brain CT demonstrated an enhanced mass lesion over bilateral frontal lobes (Figure 1 ). Severe mass effect, perifocal edema, and collapse of the left lateral ventricle were also noted. The patient was thus re-ferred to our neurosurgical clinic for further evaluation.
Neurologic examination elicited several positive findings, including bilateral abducens palsy and decreased muscle power of right limbs to grade IV. The patient's consciousness was clear and no sensory deficit was detected. Coordination was intact. Results of the rest of the physical examination were normal.
Gadolinium-enhanced MRI of the brain demonstrated a multilobulated giant heterogeneous mass lesion of about 7 × 8 × 6 cm, based on the anterior cerebral falx, occupying the bilateral frontal lobes and left high parietal lobe with intense enhancement (Figure 2 ). This mass and associated severe perifocal edema resulted in compression of bilateral lateral ventricles, the third ventricle, left thalamus, and left basal ganglia. A preoperative presumptive diagnosis of aggressive meningioma, or possibly hemangiopericytoma, was made.
The patient underwent bicoronal craniotomy on December 28, 2000. Gross total resection of the tumor was performed. The tumor was multilobulated and attached to the anterior cerebral falx. Grossly, it was reddish-brown and rubbery hard. The main part of the tumor was located in the left frontal lobe with partial erosion of the anterior cerebral falx and extension into the right frontal and left parietal lobes. Loose adhesion between the tumor and the neighboring falx was noted. There was no evidence of invasion to the dura or skull bone. The postoperative course was smooth except for transient diabetes insipidus for 3 days that subsided without adverse postoperative sequelae.
Light microscopic examination of the tumor specimen demonstrated a bimorphic pattern ( Figure 3A) . The tumor was composed of undifferentiated round or spindle-shaped cells and islets of cartilaginous tissue. The primitive undifferentiated cells possessed round or ovoid hyperchromatic nuclei and scanty, poorly outlined, eosinophilic cytoplasm ( Figure 3B ). They were arranged in a hemangiopericytomatous pattern around the vascular cleft. The cartilaginous foci were generally well defined. There was often an abrupt transition between the cartilaginous and undifferentiated areas. In addition, occasional areas of necrosis or hemorrhage were seen. Immunohistochemical examination of the cartilaginous portion of the tumor was positive for S-100 protein ( Figure 3C ). The undifferentiated tumor cells were positive for vimentin but negative for glial fibrillary acidic protein, neuron-specific enolase, and cytokeratin. A pathologic diagnosis of extraskeletal mesenchymal chondrosarcoma was made.
Postoperatively, the neurologic deficit was in complete remission. The patient was discharged home 11 days after surgery without postoperative adjuvant radiotherapy or chemotherapy. Her school performance was much improved in the follow-up period. Serial MRI studies revealed no evidence of recurrence 30 months after surgery ( Figure 4 ).
DISCUSSION
Mesenchymal chondrosarcoma is a high-grade malignant neoplasm with a very high tendency to local recurrence and 
B A C
distant metastasis [5, 6] . It was first described as an unusual malignant neoplasm arising from bone that resembles primitive cartilaginous mesenchyme. After the first report of an extraskeletal intracranial mesenchymal chondrosarcoma in 1962 by Dahlin and Henderson [7] , there were 37 cases reported in the English literature (Table) . Most extraskeletal intracranial mesenchymal chondrosarcomas have been reported in patients in their second or third decade of life, with a slight female preponderance [2, 13, 19, 26] . The most common location of this tumor in the central nervous system is the craniospinal meninges [6] . Typically, such tumors are supratentorial, most often found in the frontoparietal region, and are attached to the meninges. Sometimes, the tumor may closely resemble a hemangiopericytoma or a cartilage-containing meningioma under light microscopy, especially when a limited amount of biopsy specimen that does not contain the cartilaginous elements is provided to the pathologist [27] . An intracranial mesenchymal chondrosarcoma can be very difficult to differentiate from a meningioma by radiologic studies. The tumors are hypointense to normointense on T1-weighted MRI and have strong enhancement. They can resemble malignant meningioma or hemangiopericytoma. These lesions are extremely hypervascular on angiographic examination, and embolization may be necessary before surgery [13, 16] .
On pathologic examination, the tumor is usually well circumscribed, rubbery firm, multilobulated, reddish-brown or gray, and often invasive. The cut surface is bloody with prominent vascularity and focal calcification. Microscopic examination shows some specific characteristics. The tumor has two distinct components: highly cellular and undifferentiated mesenchymal cells on the one hand, and islands of well-differentiated, benign-appearing cartilage on the other. The transition between these two components is frequently abrupt. Immunohistochemically, mesenchymal cells stain positive for vimentin but negative for glial fibrillary acidic protein and neuron-specific enolase. The chondroid cells stain positive for S-100 protein. Therefore, mesenchymal chondrosarcoma can be differentiated from meningioma or hemangiopericytoma largely by light microscopy and specific immunohistochemical staining.
The origin of the tumor is still under investigation. It was thought to originate from the embryonal cartilaginous rests in the cranial bones and dura, from the meningeal fibroblasts, or from the multipotent mesenchymal cells in the dura or arachnoid [28, 29] . The latter theory is more popular. One study even indicated that mesenchymal chondrosarcoma was the neoplasm of differentiating premesenchymal chondroprogenitor cells [30] . Such early mesenchymal precursor cells are not restricted to bone but are found throughout the body. Mesenchymal chondrosarcomas have not been very well characterized cytogenetically, partly because the chromosomal aberrations reported are usually complex and heterogeneous. Sainati et al suggested a histogenetic relationship between mesenchymal chondrosarcoma, Ewing sarcoma, and primitive neuroectodermal tumor, with the observation of a translocation of chromosomes 11 and 22 in all three categories of tumor [31] . Szymanska et al reported an extraskeletal mesenchymal chondrosarcoma with clonal aberrations such as t(1;20)(q21;q13), t(4;9)(q23,q22), and loss of chromosomes 4, 21, and 22 in the metaphase [32] . Naumann et al reported one skeletal and one extraskeletal mesenchymal chondrosarcoma with an identical Robertsonian translocation, der(13;21)(q10;q10) [33] . Both cases also exhibited loss of all or a portion of chromosomes 8 and 20, and gain of all or a portion of chromosome 12. If additional studies confirm these data, this might lead to the identification of the genes central to the neoplastic process.
Extraskeletal mesenchymal chondrosarcoma has a high tendency to be locally aggressive, with recurrence; it is the most malignant subtype of chondrosarcoma [1] . The 5-year survival rate has been reported to range from 42% to 68%, and the 10-year survival rate from 28% to 32% [15, 34] . The tumor has the propensity not only for local recurrence but also for distant metastasis. It can metastasize to the lumbar vertebrae [15] , the ribs [13] , and to the heart and several intra-abdominal organs [11] . One patient developed leptomeningeal dissemination of the tumor after treatment [23] .
Among the reported cases, 20 patients died 3 days to 9 years after surgery (mean, 40 months). Fourteen patients had recurrence after surgery, while nine patients did not have recurrence 5 months to 4.5 years (mean, 23 months) after surgical resection. Our patient experienced no evidence of recurrence for at least 30 months after surgery. Diplopia and muscle weakness subsided considerably. No major neurologic deficit persisted after surgery. Her performance in junior high school was much improved.
The optimal treatment for extraskeletal intracranial mesenchymal chondrosarcoma is radical surgical excision of the tumor, if possible [4, 28, 35] . Some authors recommend that radiotherapy with or without concomitant chemotherapy should be considered for treatment of patients with unresectable mesenchymal chondrosarcoma and for those in whom the surgical margins are inadequate after radical surgical excision [5] . However, the potential benefits of radiotherapy and chemotherapy remain controversial because of the rarity of the tumor.
CONCLUSION
Extraskeletal intracranial mesenchymal chondrosarcoma is a rare malignant tumor, with a strong tendency to local aggression and distant metastasis. It occurs mainly in young adulthood and can be mistaken for a meningioma or hemangiopericytoma on radiologic studies. Thus, this aggressive tumor should be considered in the differential diagnosis of an enhancing mass in the frontoparietal region, especially in adolescent and young adult patients. A sufficient biopsy specimen should be obtained due to the biphasic nature of the tumor; limited specimen size may result in misdiagnosis. The mainstay of treatment is aggressive radical resection, if possible, with close postoperative follow-up, because it offers the greatest opportunity for a long-term, recurrence-free period for patients, although the long-term outcomes may be disappointing. Radiotherapy and chemotherapy may be considered to reduce the risk of recurrence, or to treat patients with unresectable tumors and for those in whom the surgical margins are inadequate after radical surgery. However, the benefits of radiotherapy and chemotherapy are unclear and further investigation is necessary.
